Fig. 2
From: The oncogenic role of the In1-ghrelin splicing variant in prostate cancer aggressiveness
Effects of ghrelin and In1-ghrelin on normal prostate cell functions. a. Ghrelin and In1-ghrelin derived peptides (In1–19 and In1–40) actions on free cytosolic calcium levels ([Ca2+]i) in normal prostate single-cell from primary cultures (10 nM; n ≥ 3). Total number of cells measured, percentage of responsive cells (% of cells resp.), percentage of maximum response (±error) and time of maximal response (±error) are indicated. Representative profiles of changes in [Ca2+]i in response to ghrelin, In1–19 and In1–40 are also depicted; b. PSA protein secretion after 4 or 24 h of treatment with ghrelin or In1-ghrelin derived peptides (10 nM) in primary normal prostate cell cultures; c. PSA mRNA expression after 4 or 24 h of treatment with ghrelin or In1-ghrelin derived peptides (10 nM) in primary normal prostate cell cultures; d. Cell viability of normal prostate cell cultures after treatment with vehicle-control, ghrelin or In1-ghrelin derived peptides for 4-24 h (n ≥ 3); e. Cell proliferation of normal prostate RWPE-1 cell line after treatment with vehicle-control, ghrelin or In1-ghrelin derived peptides for 4-24 h (n ≥ 3). f. Cell viability of normal prostate cell cultures transfected with empty (mock), ghrelin or In1-ghrelin vectors and determined after 24-48 h (n ≥ 3). Asterisk represent significant differences (*p < 0.05; ***p < 0.001) between control and ghrelin or In1-ghrelin effects (treatment or transfection). Data represent mean ± SEM